Trial Profile
A Randomized, Phase 2 Study to Assess the Safety and Efficacy of CRLX101 in Combination With Bevacizumab in Patients With Metastatic Renal Cell Carcinoma (RCC) Versus Standard of Care (SOC) (Investigator's Choice)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 24 May 2019
Price :
$35
*
At a glance
- Drugs Camptothecin (Primary) ; Bevacizumab
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- Sponsors Cerulean Pharma
- 11 Sep 2017 Results assessing safety and efficacy of CRLX101 in combination with bevacizumab versus standard of care in patients with advanced renal cell carcinoma, were published in the Annals of Oncology.
- 17 Aug 2016 According to a Cerulean Pharma media release, the full data set from the trial are expected to be submitted for presentation at an upcoming medical conference.
- 17 Aug 2016 Results published in Cerulean Pharma Inc media release.